United States NASH Therapeutic Drugs Market was valued at USD 0.7 Billion in 2022 and is projected to reach USD 3.2 Billion by 2030, growing at a CAGR of 20.3% from 2024 to 2030.
The US NASH Therapeutic Drugs Market has been steadily expanding as the need for effective treatments for Non-Alcoholic Steatohepatitis (NASH) rises. NASH, a severe form of non-alcoholic fatty liver disease (NAFLD), is a growing concern due to its increasing prevalence, particularly among adults in the United States. The market for therapeutic drugs targeting NASH is experiencing heightened demand from healthcare providers, pharmaceutical companies, and patients alike, as they seek solutions for this potentially life-threatening condition.
The key drivers behind the market's growth include the escalating number of NASH diagnoses, rising awareness about the disease, and the increasing focus on developing specialized drugs. The primary requirement from industries is the availability of highly effective, safe, and long-term therapies that can target the various stages of NASH progression, from simple steatosis to advanced fibrosis and cirrhosis. In addition to these, the need for drugs that can address the underlying metabolic and genetic factors contributing to NASH is also a significant factor driving market growth.
The US market is characterized by a diverse range of pharmaceutical companies and biotech firms working on the development of NASH therapeutic drugs. These companies are exploring various mechanisms of action, including anti-fibrotic agents, metabolic regulators, and immune modulators. The challenge lies in finding treatments that are not only effective but also have minimal side effects, as patients with NASH are often already at risk of other co-morbidities like obesity, diabetes, and cardiovascular diseases.
As the demand for NASH Therapeutic Drugs increases, industries are also focusing on the need for faster regulatory approval processes and clinical trials. The FDA's support for new treatments, combined with increased research funding, has created a favorable environment for innovation. Pharmaceutical companies are also investing in biomarkers and diagnostic tools to better understand the disease's progression, allowing for more precise and effective drug development.
The US NASH Therapeutic Drugs Market is becoming an essential segment in the healthcare and pharmaceutical industries. With a growing patient base and innovative treatment approaches, there is no doubt that the demand for effective NASH therapies will continue to rise, prompting further advancements in the treatment landscape.
Get an In-Depth Research Analysis of the US NASH Therapeutic Drugs Market Size And Forecast [2025-2032]
Allergan Plc (Tobira)
Bristol Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences
Inc.
Intercept Pharmaceuticals
Inc.
Zydus Cadila
By the year 2030, the scale for growth in the market research industry is reported to be above 120 billion which further indicates its projected compound annual growth rate (CAGR), of more than 5.8% from 2023 to 2030. There have also been disruptions in the industry due to advancements in machine learning, artificial intelligence and data analytics There is predictive analysis and real time information about consumers which such technologies provide to the companies enabling them to make better and precise decisions. The Asia-Pacific region is expected to be a key driver of growth, accounting for more than 35% of total revenue growth. In addition, new innovative techniques such as mobile surveys, social listening, and online panels, which emphasize speed, precision, and customization, are also transforming this particular sector.
Get Discount On The Purchase of the US NASH Therapeutic Drugs Market Size And Forecast [2025-2032]
Growing demand for below applications around the world has had a direct impact on the growth of the US NASH Therapeutic Drugs Market
Immunosuppressants
Antifibrotic Drugs
Enzyme Inhibitors
Metabolic Regulators
Oral Drugs
Injectable Drugs
Antioxidants
Pro-inflammatory Cytokine Modulators
Hepatocyte Protection Agents
Fibrosis Inhibitors
Preclinical
Phase I
Phase II
Phase III
Marketed
Oral
Parenteral
US (United States, US and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, Indonesia, Thailand, Philippines, Malaysia and Vietnam)
South America (Brazil, Argentina, Columbia, etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
For More Information or Query, Visit @ NASH Therapeutic Drugs Market Research Analysis
1. Introduction of the US NASH Therapeutic Drugs Market
Overview of the Market
Scope of Report
Assumptions
2. Executive Summary
3. Research Methodology of Verified Market Reports
Data Mining
Validation
Primary Interviews
List of Data Sources
4. US NASH Therapeutic Drugs Market Outlook
Overview
Market Dynamics
Drivers
Restraints
Opportunities
Porters Five Force Model
Value Chain Analysis
5. US NASH Therapeutic Drugs Market, By Type
6. US NASH Therapeutic Drugs Market, By Application
7. US NASH Therapeutic Drugs Market, By Geography
US
Europe
Asia Pacific
Rest of the World
8. US NASH Therapeutic Drugs Market Competitive Landscape
Overview
Company Market Ranking
Key Development Strategies
9. Company Profiles
10. Appendix
About Us: Verified Market Reports
Verified Market Reports is a leading US Research and Consulting firm servicing over 5000+ US clients. We provide advanced analytical research solutions while offering information-enriched research studies. We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.
Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.
Contact us:
Mr. Edwyne Fernandes
US: +1 (650)-781-4080
US Toll-Free: +1 (800)-782-1768
Website: https://www.verifiedmarketreports.com/